KIT mutants:PI3K catalyze synthesis of PIP3

Stable Identifier
R-HSA-9670433
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane, cytosol, extracellular region
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
KIT mutants:PI3K catalyze synthesis of PIP3
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
PI3K/AKT signaling is initiated downstream of KIT juxtamembrane and kinase domain mutants, as assessed by the presence of phosphorylated AKT in Western analysis (Kemmer et al, 2004; Nakai et al, 2005; Duensing et al, 2004; Tarn et al, 2006; Rossi et al, 2006; Bauer et al, 2007; Bosbach et al, 2017; Zhu et sl, 2007; Serrano et al, 2019; reviewed in Lennartsson and Roonstrand, 2012).
Literature References
PubMed ID Title Journal Year
23073628 Stem cell factor receptor/c-Kit: from basic science to clinical implications

Lennartsson, J, Rönnstrand, L

Physiol. Rev. 2012
14695343 KIT mutations are common in testicular seminomas

Kemmer, K, Corless, CL, Fletcher, JA, McGreevey, L, Haley, A, Griffith, D, Cummings, OW, Wait, C, Town, A, Heinrich, MC

Am. J. Pathol. 2004
16707477 Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms

Tarn, C, Skorobogatko, YV, Taguchi, T, Eisenberg, B, von Mehren, M, Godwin, AK

Cancer Res. 2006
15007386 Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)

Duensing, A, Medeiros, F, McConarty, B, Joseph, NE, Panigrahy, D, Singer, S, Fletcher, CD, Demetri, GD, Fletcher, JA

Oncogene 2004
16188233 KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors

Nakai, Y, Nonomura, N, Oka, D, Shiba, M, Arai, Y, Nakayama, M, Inoue, H, Nishimura, K, Aozasa, K, Mizutani, Y, Miki, T, Okuyama, A

Biochem. Biophys. Res. Commun. 2005
30792533 Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

Serrano, C, Mariño-Enríquez, A, Tao, DL, Ketzer, J, Eilers, G, Zhu, M, Yu, C, Mannan, AM, Rubin, BP, Demetri, GD, Raut, CP, Presnell, A, McKinley, A, Heinrich, MC, Czaplinski, JT, Sicinska, E, Bauer, S, George, S, Fletcher, JA

Br. J. Cancer 2019
28923937 Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor

Bosbach, B, Rossi, F, Yozgat, Y, Loo, J, Zhang, JQ, Berrozpe, G, Warpinski, K, Ehlers, I, Veach, D, Kwok, A, Manova, K, Antonescu, CR, DeMatteo, RP, Besmer, P

Proc. Natl. Acad. Sci. U.S.A. 2017
17546049 KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

Bauer, S, Duensing, A, Demetri, GD, Fletcher, JA

Oncogene 2007
Participants
Input
Output
Participates
as an event of
Catalyst Activity

1-phosphatidylinositol-3-kinase activity of PI3K:p-KIT mutant dimers [plasma membrane]

Physical Entity
PI3K:p-KIT mutant dimers [plasma membrane] (Homo sapiens)
Activity
1-phosphatidylinositol-3-kinase activity (GO:0016303)
Normal reaction
Synthesis of PIP3 from PIP2 by PI3K (Homo sapiens)
Functional status

Gain of function of PI3K:p-KIT mutant dimers [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
RHEA
Mondo
Authored
Rothfels, K  (2020-04-01)
Reviewed
Serrano, C  (2020-03-13)
García-Valverde, A  (2020-03-13)
Pilco-Janeta, D  (2020-03-13)
Created
Rothfels, K  (2019-12-09)
Cite Us!